Adagrasib (MRTX849), a Potent KRAS G12C Inhibitor for KRAS G12C-mutated Locally Advanced or Metastatic NSCLC Research
On December 12, 2022, FDA granted accelerated approval to Adagrasib (Krazati), for adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC. In 2021, FDA approved the selective KRASG12C mutant inhibitor Sotorasib (AMG 510) as a second-line treatment of KRASG12C mutation-positive NSCLC. As a result, Adagrasib (MRTX849) is the...